Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases

Zeyad A. Alzahrani1,2,4 · Khalid Abdullah Alghamdi2,4 · Ahmed Saeed Almaqati3,4

Received: 8 February 2021 / Accepted: 1 April 2021 / Published online: 15 April 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases and identify the risk factors associated with severe COVID-19 pneumonia. This was a retrospective study in a tertiary care center conducted through the period between March 2020 and November 2020 and included all adult patients with rheumatic diseases who tested positive on the COVID-19 polymerase chain reaction (PCR) test. We assessed the patients’ demographic data, history of rheumatic disease, COVID-19 symptoms and experimental treatment, if any, their disease course, and outcome. In all, 47 patients were included, and most were females. The commonest rheumatic diseases were rheumatoid arthritis (53.2%), followed by systemic lupus erythematosus (21.3%), and psoriatic arthritis (10.6%). Methotrexate and hydroxychloroquine were the most commonly used disease-modifying anti-rheumatic drugs in 36.1% and 25.5%, respectively. Out of 47 patients, 48.9% required hospitalization with a median hospital stay of 7 days. Severe COVID-19 pneumonia, defined as clinical signs of pneumonia plus one of the following: respiratory rate > 30 bpm, severe respiratory distress, or oxygen saturation < 90% in room air was observed in 19.1% of the patients, and one patient died. We found that elderly patients with a mean age of 65.3 years were more likely to develop severe COVID-19 pneumonia and that was statistically significant. Our study showed that elderly patients with a mean age of 65 years and having rheumatic diseases had an increased risk of hospital admission and development of severe COVID-19 pneumonia.

Keywords COVID-19 · Rheumatic diseases · Antirheumatic drugs

Introduction
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. It was first reported in Wuhan, China, after a cluster of cases of community-acquired pneumonia showed similar clinical and biochemical characteristics. COVID-19 symptoms and outcomes range from asymptomatic with a benign course to multi-organ failure and acute respiratory distress syndrome (ARDS) and death [1]. To date, more than 100 million cases have been reported, with more than 2.2 million deaths worldwide [2]. The World health organization (WHO) has defined the severity of COVID-19 in adult patients based on the clinical and radiological presentations into mild, moderate, severe, and critical. Mild COVID-19 is defined as asymptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia. Moderate disease is defined as the presence of clinical signs of pneumonia, e.g., fever, cough, dyspnea, high respiratory rate, without signs of severe pneumonia, including SpO₂ of ≥ 90% in room air. Severe COVID-19 pneumonia is defined as the presence of clinical signs of pneumonia plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO₂ < 90% in room air. Finally, critical disease is considered as the development of sepsis, septic shock, ARDS, or acute thrombosis [3]. Multiple poor prognostic factors have
been identified, including advanced age, obesity, smoking history, diabetes mellitus, and immunosuppression [4].

Patients with rheumatic diseases are predisposed to infections due to their disease background, especially when they have active disease and when they are on immunosuppressive medications. However, during the COVID-19 pandemic, conflicting results of the clinical course were seen in patients with connective tissue diseases infected with SARS-CoV-2. A study by Pablos et al. found that patients with connective tissue diseases are more likely to develop severe COVID-19 [5]. In contrast, a case series from New York showed that there was no difference in the rate of hospitalization between patients with immune-mediated inflammatory diseases and the general population [6].

In patients with connective tissue diseases, available data from the COVID-19 Global Rheumatology Alliance physician-reported registry found that the use of conventional disease-modifying anti-rheumatic drugs (DMARDs) alone or in combination with biologics/Janus Kinase inhibitors was not associated with an increased rate of hospitalization [7]. Several medications that are used in the treatment of different rheumatic diseases have been explored for the treatment of COVID-19, e.g., hydroxychloroquine [8], corticosteroids [9], tocilizumab [10], and anti-TNF with variable results. A systematic review and meta-analysis by Michael Putman et al. that included 45 articles reporting the use of anti-rheumatic therapies in COVID-19 treatment found that hydroxychloroquine did not significantly change the COVID-19 outcome. Two cohort studies with a high risk of bias showed that anakinra were associated with decreased mortality rate. Evidence about other anti-rheumatic therapies in the treatment of COVID-19 was inconclusive [11].

Therefore, due to a paucity of research data about COVID-19 in patients with rheumatic diseases in our region, we conducted this study to assess the baseline characteristics and clinical outcomes of COVID-19 in these patients and determine the risk factors associated with the development of severe COVID-19.

**Methods**

This was a single-center study conducted in a tertiary care center in the Western Region of Saudi Arabia.

**Patients**

The study included all adult patients aged ≥ 18 years who tested positive on the COVID-19 polymerase chain reaction (PCR) test and had been diagnosed with rheumatic diseases based on the approved classification criteria. We included patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), mixed connective tissue disease (MCTD), Sjogren’s syndrome, dermatomyositis, polymyositis, spondyloarthritis (SpA), and juvenile idiopathic arthritis (JIA). Patients with crystal-induced arthritis, fibromyalgia, and osteoarthritis were excluded from the study as the management of these conditions does not include immunosuppressive medications.

We included all patients who met our inclusion criteria in the study during the period between March 2020 and November 2020. The patients’ electronic medical records were reviewed, and their demographic and clinical data were collected by trained rheumatologists.

**Main outcome variable**

There is no age cut-off defined by the WHO to categorize the elderly population; however, the United Nations (UN) refers to elderly individuals as those aged 60 years and above. We considered this age as the cut-off to define advanced age in our cohort [12]. We defined severe COVID-19 pneumonia based on the WHO guidance as the presence of clinical signs of pneumonia plus one of the following: respiratory rate > 30 bpm, severe respiratory distress, or oxygen saturation < 90% in room air.

Our data collection sheet included the patients’ demographic data, history of rheumatic disease, COVID-19 symptoms, COVID-19 experimental treatment, the clinical course of the disease, and outcome. The patients’ demographic data included age, sex, body mass index (BMI), and history of smoking and diabetes. In addition, details of the rheumatic disease, including the type of rheumatic disease, intake of steroids or disease-modifying anti-rheumatic drugs (DMARDs) at the time of diagnosis, and whether if it were held during COVID-19 illness or not. We also collected data about the course of COVID-19, including receiving experimental treatment, need for hospitalization, ICU admission, oxygen therapy or invasive ventilation, and/or death.

**Procedures**

The diagnosis of COVID-19 was confirmed as a positive test of samples obtained by nasopharyngeal swab and tested on the approved diagnostic reverse transcription-polymerase chain reaction (RT-PCR) test, the RealStar® SARS-CoV-2 RT-PCR kit 1.0 (Altona Diagnostics, Hamburg, Germany).

**Statistical analysis**

Descriptive statistics are presented as numbers, percentages, mean, standard deviation, and median (min–max) whenever appropriate. Between comparisons, Fisher’s Exact test, independent t-test, or Mann Whitney U test were applied, and a p value < 0.05 was considered statistically significant. The normality of variables was tested using the
Kolmogorov–Smirnov test, as well as the Shapiro–Wilk test. The data showed normal distribution; thus, parametric methods were applied. All data analyses were performed using Statistical Packages for Social Sciences (SPSS) version 21 Armonk, NY: IBM Corporation.

Results

We analyzed the clinical characteristics of 47 patients with an established diagnosis of rheumatic disease who tested positive for COVID-19. The mean age of the patients was 50.8 ± 17.1 years, and most of them were females (87.2%). The median BMI value was 28 kg/m² (14–59 kg/m²). The prevalence of smoking was 8.5%, and that of diabetes was 14.9%. The proportion of patients taking steroids was 44.7%, while that of those taking DMARDs was 93.6%. However, almost 60% of the patients had discontinued medication due to COVID-19 illness, as shown in Table 1.

In the study cohort, the most prevalent rheumatic diseases were RA (53.2%), followed by SLE (21.3%), and PsA (10.6%). The mean rheumatic diseases duration was 7 ± 4 years. The most commonly used DMARDs were methotrexate (36.1%) followed by hydroxychloroquine (25.5%), as presented in Table 1.

With respect to the COVID-19 symptoms and receiving experimental treatment, only one patient was asymptomatic, as shown in Table 2. The most commonly reported symptoms were fever and myalgia (78.7% each), followed by cough (74.5%) and arthralgia (70.2%). The incidence of gastrointestinal symptoms was the lowest, with nausea and vomiting seen in 25.5% of the patients. Furthermore, 19.1% of the patients received experimental treatment for COVID-19, with dexamethasone being the most commonly prescribed medication (66.7%).

Almost 50% of the patients were admitted to the hospital with a median hospital stay of 7 days (1–111). Only 16 patients (34%) had evidence of pneumonia, of which only nine met the guidance criteria for severe COVID-19 pneumonia. Five patients (10.6%) were admitted to the intensive care unit (ICU), and three patients required invasive ventilation (6.4%). One elderly patient with RA who was on rituximab therapy died during the course of the study.

All the three patients who required invasive ventilation were females who were on baseline DMARDs: rituximab, adalimumab, and etanercept, respectively, which were discontinued during the COVID-19 illness. Of these, the patient who died had received her rituximab dose five months prior to the COVID-19 infection.

On analyzing the characteristics of patients with severe COVID-19 pneumonia, it was found that advanced age with a mean of 65.3 years was the only statistically significant factor (p = 0.003). This was about 18 years older than those who did not develop severe disease. Other baseline characteristics did not significantly influence the course of the disease (all p > 0.05), as presented in Table 3. Among those with severe COVID-19, 8 out of 9 patients were females. None of the nine patients were smokers, and all of them were on DMARDs; however, seven patients (77.8%) had

| Study variables | N (%) |
|-----------------|-------|
| Age in years (mean ± SD) | 50.8 ± 17.1 |
| BMI kg/m² [median (min–max)] | 28.0 (14–59) |
| Gender | |
| Male | 6 (12.8%) |
| Female | 41 (87.2%) |
| Smoking | |
| Yes | 4 (08.5%) |
| Diabetes | |
| Yes | 7 (14.9%) |
| Steroids use | |
| Yes | 21 (44.7%) |
| Disease-modifying anti-rheumatic drugs (DMARDs) use | |
| Yes | 44 (93.6%) |
| Stopped medications during COVID-19 illness | |
| Yes | 28 (59.6%) |
| Type of rheumatic disease | |
| Rheumatoid arthritis | 25 (53.2%) |
| Systemic lupus erythematosus | 10 (21.3%) |
| Psoriatic arthritis | 5 (10.6%) |
| Mixed connective tissue disease | 2 (4.3%) |
| Sjogren’s syndrome | 1 (2.1%) |
| Dermatomyositis | 1 (2.1%) |
| Polymyositis | 1 (2.1%) |
| Spondyloarthritis | 1 (2.1%) |
| Juvenile idiopathic arthritis | 1 (2.1%) |
| Rheumatic diseases duration in years (mean ± SD) | 7 ± 4 |
| Baseline DMARDs | |
| Methotrexate | 17 (36.1%) |
| Hydroxychloroquine | 12 (25.5%) |
| Methotrexate plus adalimumab | 4 (8.5%) |
| Adalimumab | 2 (4.3%) |
| Hydroxychloroquine plus azathioprine | 1 (2.1%) |
| Hydroxychloroquine plus rituximab | 1 (2.1%) |
| Methotrexate plus etanercept | 1 (2.1%) |
| Canakinumab | 1 (2.1%) |
| Secukinumab | 1 (2.1%) |
| Etanercept | 1 (2.1%) |
| Tocilizumab | 1 (2.1%) |
| Azathioprine | 1 (2.1%) |
| Rituximab | 1 (2.1%) |
| Off DMARDs | 3 (6.4%) |
discontinued their medications due to COVID-19 illness. RA was the most prevalent rheumatic disease (55.6%), followed by PsA (22.2%), while the most commonly used DMARDs were hydroxychloroquine, methotrexate, and the combination of methotrexate with adalimumab (22.2% each).

**Discussion**

This study conducted in a tertiary care hospital presents the baseline characteristics of patients with rheumatic diseases who were infected with SARS-CoV-2. Older patients with a mean age of 65.3 years were found to be at a higher risk of getting severe COVID-19 pneumonia, which is consistent with multiple previously reported studies. Data from the French RMD COVID-19 cohort reported that age was a risk factor for severe disease; only 11 patients between the age of 18 and 54 years developed severe COVID-19, while cases increased to 20 between the age of 65 and 74 years and to 45 in patients > 75 years [13]. Furthermore, the mortality rate was higher in the elderly patients, as shown in a recent publication by the COVID-19 Global Rheumatology Alliance physician-reported registry, which found that 68.7% of those who died were > 65 years old [14].

Most of our study subjects were female (87.2%), which is consistent with the natural history of female predominance in autoimmune diseases. This reflects the higher percentage of females developing severe COVID-19 pneumonia (88.9%) and those who required invasive ventilation in our cohort. This is in contrast to multiple reported papers from different geographical areas [15, 16]. For instance, the COVID-19 Global Rheumatology Alliance physician-reported registry found that there was no significant difference in the rate of hospitalization based on sex [7]. However, sex was not found to be a statistically significant factor for hospital admission or severity of the disease. In addition, we found a low prevalence of smoking in our subjects; however, none of the smokers developed severe COVID-19 pneumonia, which is not in line with a large meta-analysis by Patanavanich et al. who found that smoking was associated with poor prognosis [17]. These differences could be due to the small sample size in our study and the low prevalence of female smokers in the Saudi culture.

In a study by Zhong et al., they traced patients with rheumatic diseases who lived with family members who were tested positive for SARS-CoV-2. They found that patients with rheumatic diseases had a higher predisposition for SARS-CoV-2 infection compared to other family members [18]. Moreover, adjusted multivariable analysis by Freites Nuñez et al. for sex, age, and comorbidities associated with COVID-19 found that higher age and presence of autoimmune diseases had a higher probability of hospitalization, regardless of other factors [19]. Furthermore, a comparative cohort study by D’Silva et al. found that a history of rheumatic disease was associated with an increased rate of invasive ventilation than the control group, though both had identical clinical features and rates of hospitalization [20]. Nevertheless, no specific rheumatic disease was found to be a statistically significant risk factor for hospitalization or severity of the disease in our study. However, multivariate analysis in a study by Fernandez-Gutierrez et al. showed that some autoimmune diseases, namely Sjogren’s syndrome, polychondritis, Raynaud, and MCTD, are associated with COVID-19 found that higher age and presence of autoimmune diseases had a higher probability of hospitalization, regardless of other factors [19]. Furthermore, a comparative cohort study by D’Silva et al. found that a history of rheumatic disease was associated with an increased rate of invasive ventilation than the control group, though both had identical clinical features and rates of hospitalization [20]. Nevertheless, no specific rheumatic disease was found to be a statistically significant risk factor for hospitalization or severity of the disease in our study. However, multivariate analysis in a study by Fernandez-Gutierrez et al. showed that some autoimmune diseases, namely Sjogren’s syndrome, polychondritis, Raynaud, and MCTD, are associated with higher rates of hospital admissions [21]. Among risk factors other than rheumatic diseases, the Brescia Rheumatology COVID-19 Study Group found no difference in the comorbidities between deceased or alive patients [22]. In contrast, a recent review concluded that not only rheumatic diseases can affect COVID-19 outcome, but also the other comorbidities those patients have, which necessitates patients stratification based on the presence and number of comorbidities especially during the pandemic to aid in predicting outcome [23].

Our study showed that no specific DMARDs were associated with severe COVID-19 pneumonia, and none of them was found to be statistically significant, which is similar to the results of a study by Santos et al. [24] Likewise, another publication showed similar findings, wherein baseline rheumatic therapies did not alter the mortality

**Table 2 COVID-19 symptoms and experimental treatment (n = 47)**

| Variables | N (%) |
|-----------|-------|
| Asymptomatic | Yes 1 (2.1%) |
| Symptomsa | Fever 37 (78.7%) |
|           | Myalgia 37 (78.7%) |
|           | Cough 35 (74.5%) |
|           | Arthralgia 33 (70.2%) |
|           | Dyspnea 29 (61.7%) |
|           | Loss of smell 29 (61.7%) |
|           | Headache 29 (61.7%) |
|           | Loss of taste 28 (59.6%) |
|           | Sore throat 22 (46.8%) |
|           | Diarrhea 18 (38.3%) |
|           | Nausea and/or vomiting 12 (25.5%) |
| Received COVID-19 experimental treatment | Yes 9 (19.1%) |
| Dexamethasone | 6 (66.7%) |
| Tocilizumab | 1 (11.1%) |
| Dexamethasone + tocilizumab | 1 (11.1%) |
| Hydroxychloroquine + azithromycin | 1 (11.1%) |

aVariable with multiple responses
Table 3  Characteristics of severe COVID-19 pneumonia (n = 47)

| Factor                                      | Severe COVID-19 | X²   | p value § |
|---------------------------------------------|-----------------|------|-----------|
|                                             | Yes (n = 09)    | No   (n = 38) |           |
|                                             |                 |      |           |
| Age in years (mean ± SD) a                  | 65.3 ± 14.5     | 47.3 ± 16.0 | 3.083 0.003** |
| BMI kg/m² [median (min–max)] b               | 29.5 (22–39)    | 28.5 (14–59) | 0.110 0.925 |
| Gender                                      |                 |      |           |
| Male                                        | 1 (11.1%)       | 5 (13.2%) | 0.027 1.000 |
| Female                                      | 8 (88.9%)       | 33 (86.8%) |           |
| Smoking                                     |                 |      |           |
| Yes                                         | 0               | 4 (10.5%) | 1.035 0.574 |
| No                                          | 9 (100%)        | 34 (89.5%) |           |
| Diabetes                                    |                 |      |           |
| Yes                                         | 3 (33.3%)       | 4 (10.5%) | 2.986 0.084 |
| No                                          | 6 (66.7%)       | 34 (89.5%) |           |
| Steroids use                                |                 |      |           |
| Yes                                         | 5 (55.6%)       | 16 (42.1%) | 0.533 0.486 |
| No                                          | 4 (44.4%)       | 22 (57.9%) |           |
| DMARDs use                                  |                 |      |           |
| Yes                                         | 9 (100%)        | 35 (92.1%) | 0.759 1.000 |
| No                                          | 0               | 3 (7.9%)   |           |
| Stopped medications during COVID-19 illness |                 |      |           |
| Yes                                         | 7 (77.8%)       | 21 (55.3%) | 1.532 0.216 |
| No                                          | 2 (22.2%)       | 17 (44.7%) |           |
| Type of rheumatic disease                   |                 |      |           |
| Rheumatoid arthritis                        | 5 (55.6%)       | 20 (52.6%) |           |
| Psoriatic arthritis                         | 2 (22.2%)       | 3 (7.9%)  |           |
| Systemic lupus erythematosus                | 1 (11.1%)       | 9 (23.7%) | 7.600 0.517 |
| Polymyositis                                | 1 (11.1%)       | 0       |           |
| Sjogren’s syndrome                          | 0               | 1 (2.6%)  |           |
| Mixed connective tissue disease             | 0               | 2 (5.3%)  |           |
| Dermatomyositis                             | 0               | 1 (2.6%)  |           |
| Spondyloarthritis                           | 0               | 1 (2.6%)  |           |
| Juvenile idiopathic arthritis               | 0               | 1 (2.6%)  |           |
| Baseline DMARDs                             |                 |      |           |
| Hydroxychloroquine                          | 2 (22.2%)       | 10 (28.6%) | 13.692 0.255 |
| Methotrexate                                | 2 (22.2%)       | 15 (42.9%) |           |
| Methotrexate + adalimumab                   | 2 (22.2%)       | 2 (5.7%)  |           |
| Adalimumab                                  | 1 (11.1%)       | 1 (2.9%)  |           |
| Etanercept                                  | 1 (11.1%)       | 0       |           |
| Rituximab                                   | 1 (11.1%)       | 0       |           |
| Azathioprine                                | 0               | 1 (2.9%)  |           |
| Tocilizumab                                 | 0               | 1 (2.9%)  |           |
| Secukinumab                                 | 0               | 1 (2.9%)  |           |
| Canakinumab                                 | 0               | 1 (2.9%)  |           |
| Methotrexate + etanercept                   | 0               | 1 (2.9%)  |           |
| Hydroxychloroquine + rituximab              | 0               | 1 (2.9%)  |           |
| Hydroxychloroquine + azathioprine           | 0               | 1 (2.9%)  |           |

a p value has been calculated using Independent t-test
b p value has been calculated using Mann Whitney U test
§ p value has been calculated using Fischer’s exact test
$ p$ value has been calculated using Fischer’s exact test
** Significant at p < 0.05 level
rate [25]. In contrast, the COVID-19 Global Rheumatology Alliance physician-reported registry found that biological DMARD/targeted synthetic DMARD monotherapy was associated with lower rates of hospital admissions [7]. However, inferred results from a systematic review suggested that patients with rheumatic diseases on chronic immunosuppressive medications are more likely to require ICU admissions and invasive ventilation [26].

Among the COVID-19 symptoms, fever, myalgia, and cough were the most commonly reported symptoms by our patients (78.7%, 78.7%, and 74.5%, respectively), which is consistent with the report of a German registry [15]. During the early days of the pandemic with a lack of evidence-based knowledge about the course of COVID-19 and the prognosis in immunocompromised patients, one of our national policies was to admit all immunocompromised patients diagnosed with COVID-19 for close monitoring, regardless of their disease severity, resulting in a high admission rate in our study (48.9%). However, only 19.1% of these patients had severe COVID-19 pneumonia based on the WHO definition [3]. Similarly, a high rate of admissions for such patients was reported in the literature, one of which was published by Freites Nuñez et al., who reported an admissions rate of 44%; however, our ICU admissions rate was higher [19]. Few of our patients received experimental treatments for COVID-19, with dexamethasone being the most frequently prescribed drug after the release of preliminary findings of the RECOVERY trial [9].

Our cohort showed a significantly low rate of mortality (2.1%) compared to multiple studies worldwide reporting a mortality rate ranging from 6 to 19% [7, 20, 27]. The only deceased patient was an elderly female who was known to have RA and was on rituximab. She was one of the two patients-receiving rituximab as baseline DMARD for their rheumatic disease, which is reported to be associated with increased adverse events and high mortality rates in patients with COVID-19 [28]. The patient’s hospital course was complicated with the development of cytokine release syndrome, for which she received an experimental tocilizumab dose and required invasive ventilation.

The following are a few limitations of our study. First, it was a single-centered study with small sample size. However, this is the first paper from our region addressing the baseline characteristics and clinical outcome of COVID-19 in patients with rheumatic diseases. The second limitation is the retrospective study design, which limits our ability to assess for rheumatic disease activity, as the patients were being managed and seen by non-rheumatologists during that COVID-19 illness. Moreover, they were isolated to minimize contact with multiple physicians. Finally, cumulative doses of steroids were not documented due to a lack of data.

**Conclusion**

The current study suggests that elderly patients with a mean age of 65 years with rheumatic diseases are more likely to have a poor outcome in terms of developing severe COVID-19 pneumonia. The other variables were not statistically significant. Further large studies are necessary in this field to assess COVID-19 outcomes in patients with rheumatic disease.

**Acknowledgements** We would like to thank Editage (http://www.edita.com) for English language editing.

**Funding** All the authors, Dr. Alzahrani, Dr. Alghamdi, and Dr. Almaqati, received no funding and has no conflict of interest to disclose.

**References**

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395(10223):497–506.
2. COVID-19 Map—Johns Hopkins Coronavirus Resource Center 2021. https://coronavirus.jhu.edu/map.html. Accessed 28 Jan 2021
3. World Health Organization (2020) Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization. https://apps.who.int/iris/handle/10665/332196. Accessed 28 Jan 2021
4. Wang L, He W, Yu X, Hu D, Bao M, Liu H et al (2020) Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 80(6):639–645
5. Pablos JL, Galindo M, Carmona L, Llledó A, Retuerto M, Blanco R et al (2020) Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 79(12):1544–1549
6. Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Iznirly P et al (2020) Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med 383(1):85–88
7. Gianfrancesco M, Hyrich KL, Al-Adey S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859–866
8. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W et al (2020) Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 369:m1849
9. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mathur M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmah E, Pradon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Landray MJ (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384(8):693–704. https://doi.org/10.1056/NEJMoa2021436
10. Malgie J, Schoones JW, Pijls BG (2020) Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis Sep 23:ciaa1445. https://doi.org/10.1093/cid/ciaa1445

© Springer
11. Putnam M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F et al (2021) Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis Rheumatol 73(1):36–47
12. World Health Organization (2021) Men, ageing and health: achieving health across the life span. World Health Organization, Geneva. Accessed 27 Jan 2021
13. FAI2R /SFR/SNFMI/SOFREMIP/CRISTIMIDIAE consortium and contributors (2020) Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 80(4):527–538. (annrheumdis-2020-218310)
14. Strangfeld A, Schafer M, Gianfrancesco MA, Lawton-Tovey S, Liew JW, Ljung L et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis (2021:annrheumdis-2020-219498)
15. Hasseli R, Mueller-Ladner U, Schmeiser T, Hoyer BF, Krause A, Lorenz HM et al (2020) National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open 6(2):e001332. https://doi.org/10.1136/rmdopen-2020-001332
16. Montero F, Marquez-Barrio J, Serrano-Benavente B, Gonzalez T, Rivera J, Molina Collada J et al (2020) Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int 40(10):1593–1598
17. Patanavanich R, Glantz SA (2020) Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res 22(9):1653–1656
18. Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L et al (2020) COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2(9):e557–e564
19. Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A et al (2020) Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(11):1393–1399
20. D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM et al (2020) Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US “hot spot.” Ann Rheum Dis 79(9):1156–1162
21. Fernandez-Gutierrez B, Leon L, Madrid A, Rodriguez-Rodriguez L, Freites D, Font J et al (2021) Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. Ther Adv Musculoskelet Dis 13:1759720X20962692
22. Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F, Brescia Rheumatology C-SG (2020) COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol 2(9):e549–e56
23. Ahmed S, Gasparyan AY, Zimba O (2021) Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 41(2):243–256. https://doi.org/10.1007/s00296-020-04764-5
24. Santos CS, Fernandez XC, Moriano Morales C, Álvarez ED, Álvarez Castro C, López Robles A et al (2021) Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe? RMD Open 7(1):e001439
25. Santos CS, Morales CM, Álvarez ED, Castro CÁ, Robles AL, Sandoval TP (2020) Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol 39(9):2789–2796
26. Rocha AP, Atallah ÁN, Pinto ACPN, Rocha-Filho CR, Milby KM, Civile VT et al (2020) COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review. Sao Paulo Med J 138:515–520
27. Sanchez-Piedra C, Diaz-Torne C, Manero I, Pego-Reigosa JM, Rúa-Figueroa I, Gonzalez-Gay MA et al (2020) Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis 79(7):988–990
28. Loarce-Martos J, García-Fernández A, López-Gutiérrez F, García-García V, Calvo-Sanz L, Del Bosque-Granero I et al (2020) High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int 40(12):2015–2021

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.